SRC and glioma: Nonetheless, conventional Src inhibitors including Dasatinib and Bosutinib have not demonstrated significant efficacy in phase II clinical trials for glioma stem cells (GSCs) or recurrent GBM due to tumor heterogeneity and the differential influence of Src family kinases on glioma growth [20,21,22].